Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.59 |
| ▸ | CTSS | P25774 | 5/20 | 0.59 |
| ▸ | CTSL | P07711 | 4/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.55 |
| ▸ | ELANE | P08246 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12590839 | 0.88 | CTSK (0.56) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL13199728 | 0.88 | CTSK (0.56) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL29504873 | 0.88 | CTSK (0.56) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL15080869 | 0.87 | CTSK (0.61) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL241564 | 0.87 | CTSK (0.61) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL856196 | 0.87 | CTSK (0.61) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL241565 | 0.87 | CTSK (0.61) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL30946598 | 0.87 | CTSK (0.61) | CTSKCTSSCTSLCTSBATM | |
| SCHEMBL6440649 | 0.86 | CTSK (0.60) | CTSKCTSSCTSLCTSBATM | |
| Hydrochloric Acid SCHEMBL7400995 | 0.86 | CTSK (0.60) | CTSKCTSSCTSLCTSBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1686996-A4 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1686996-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1651229-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | Chiron Corporation (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005051391-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050059662-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2005-03-17 | — | — | US | disclosed |
| WO-2004112793-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059662-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | CTSK 2020/4885CTSS 2449/4885CTSL 2794/4885 |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | MC4R, MC5R, MC2R | CTSK 2217/4885CTSS 2705/4885CTSL 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.